Unilife is a developer and manufacturer of advanced drug delivery systems. According to Unilife CEO Alan Shortall, the company is poised with the operational capabilities and manufacturing capacities to meet rising demands for its proprietary products. “Our ramp plans for our Unifill syringes target by the end of 2014 to be producing just under 400 million units a year,” Unilife’s Alan Shortall reports. From there, company expectations are that the production capabilities of Unilife under Alan Shortall will continue to increase. Unilife’s Alan Shortall believes that “by the end of 2016 we will be producing just under 800 million units a year.” What exactly does that represent for the pharmaceutical market for prefilled syringes? The “around 14 to 20 percent of the projected prefill syringe market at that time—which we believe is quite conservative,” says Unilife’s Alan Shortall.
Unilife’s production capability does not necessarily max out at 800 million units, says Alan Shortall. Explaining the production capabilities of Unilife, Alan Shortall says that “the lines take about 12 months from the time we order them to get them into position to start producing.” That means Unilife, Alan Shortall says, “[can] actually have the capacity to increase that ramp program further if demand requires it.”
Unilife CEO Alan Shortall says that the company has developed a plan for potential production facility expansions. “We have a planning permission already in place for an extension to that factory section,” states Unilife’s Alan Shortall. The current production facility of Unilife, says Alan Shortall, “would see us out to 400 million units of production capacity.” So when adding an expansion to the current production facility, there are few limitations to production capabilities.
Unilife’s Alan Shortall says that the current facility is “basically like building on a concrete box.” Going forward, Unilife CEO Alan Shortall describes a plan to fit out the clean rooms for that extension. “When we’ve done that we will then pull down the dividing wall so there will be no interference with our production capacity at that stage.” These changes alone can see the company “out to a billion units,” Unilife CEO Alan Shortall projects. Should that capacity be reached then Unilife, Alan Shortall states, “would be considering a secondary facility.”
Unilife Corporation is a U.S. based developer and manufacturer of a diversified portfolio of advanced drug delivery systems. Since CEO and Executive Director Alan Shortall founded Unilife in 2002, he has been a principal driving force behind the company’s rapid global expansion. At Unilife, Alan Shortall has led the Company in the development, patent-protection and diversification of its broad device portfolio, which includes a best-in-class technology platform of safety syringes. As the leader of Unilife, Alan Shortall has also attracted world-class experts from the pharmaceutical and medical device industries to the Board and executive management team.
Between 2008 and 2010, Alan Shortall spearheaded Unilife’s transition from Australia to a fully based and registered U.S. business. This included the redomiciliation of Unilife by Alan Shortall and associates into a Delaware registered Company, and its listing on the NASDAQ stock exchange (NASDAQ:UNIS) in February 2010. Unilife also continues to trade on the Australian Stock Exchange (UNS:ASX).
For more information about Alan Shortall, Unilife, or the Unifill prefill syringe, visit the company online at http://unilife.com